AcelRx Pharmaceuticals, Inc. ACRX, (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically controlled settings, announced today that it has filed a deed of amendment to its articles of incorporation to effect a reverse stock split of its common shares at a ratio of 1 :20. The reverse stock split will be effective Tuesday, October 25, 2022 at 5:01 p.m. ET. AcelRx common shares will continue to trade on the Nasdaq Global Market under the symbol ACRX and will begin trading on a split-adjusted basis when the market opens on Wednesday, October 26, 2022. The reverse stock split is intended to allow AcelRx to meet the minimum bid price of 1.00 $ required for continued listing on the Nasdaq Global Market. The new CUSIP number for AcelRx common stock following the reverse stock split is 00444T209.
